US-based Mylan has increased its offer to acquire all of outstanding shares of Ireland-based over-the-counter (OTC) and nutritional products maker Perrigo.
It will pay $75.00 per share in cash, with 2.3 Mylan ordinary shares for each ordinary Perrigo share
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The company noted that based on its closing stock price of $68.36 on April, the first day of market reaction to the initial proposal, the value of the new offer is $232.23 per Perrigo share or $34bn.
Mylan executive chairman Robert Coury said: “With this enhanced offer, I look forward to meeting with Joe Papa and his team to finalise the implementation of this truly compelling combination, which is a win-win for both Mylan and Perrigo shareholders and all other stakeholders.
“Previously, Mylan filed for US anti-trust clearance, made a ‘hell or high water’ commitment with respect to obtaining this clearance and committed to a timetable for closing. We have also secured firm committed financing for our offer.”
However, Perrigo has again rejected the increased acquisition offer, claiming that Mylan continues to propose a price lower than the previously rejected offer.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataEarlier this month, Mylan made an offer to acquire Perrigo for around $29bn in a cash and stock deal.
Morgan Stanley & Co acting through its affiliate, Morgan Stanley & Co. International plc, and JP Morgan Securities are acting as financial advisors to Perrigo.
Last week, Israel-based Teva Pharmaceutical Industries made an offer of around $40bn to acquire Mylan, but it was rejected by the US drugmaker.
Image: Photograph of the exterior of Perrigo’s Eastern Avenue Office. Photo: courtesy of Perrigo Company.
